Arch Biopartners (ARCH) Stock Price, News & Analysis

Company Overview

Arch Biopartners, Inc. (NYSE: ARCH) is a clinical-stage biopharmaceutical company focused on the development of cell and gene therapies across oncology, rare diseases, and endocrinology. The company employs an integrated venture model that builds and incubates emerging biotech entities, advancing proprietary therapeutic programs from early discovery through preclinical and clinical stages.

Headquartered in Cambridge, Massachusetts, Arch Biopartners collaborates with leading academic and research institutions throughout the United States and Europe. Its pipeline includes immuno-oncology candidates such as CAR-T cell therapies, gene therapy programs targeting inherited disorders, and regenerative medicine approaches designed to address high-unmet-need patient populations.

Guided by a management team with deep experience in biomedical research, drug development and venture investing, Arch Biopartners aims to de-risk novel assets through strategic partnerships, licensing agreements and joint ventures. The company’s venture ecosystem seeks to accelerate the translation of innovative science into potential treatment options for patients worldwide.

Key Stats

• Today's Range: $134.83 to $134.83
• 50-Day Range: $134.83 to $134.83
• 52-Week Range: $116.44 to $177.88
• Volume: N/A
• Average Volume: 391,243 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARCH Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Arch Biopartners own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Biopartners investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD) and Palo Alto Networks (PANW).

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NYSE:ARCH
• CIK: 1037676
• Web: N/A
• Phone: (647) 428-7031
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A